Professor of Medicine, University of Chicago Medicine
Hematology
Dr. Thomas F. Gajewski, MD
|
|
Give Review
Doctor Thomas F. Gajewski, MD is an expert in the field of Hematology. He went to University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Elected Member". Thomas Gajewski is a published MD. He has 98 papers published. The most current publication "A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
- Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
- The STING pathway and the T cell-inflamed tumor microenvironment.
- New perspectives on type I IFNs in Cancer.
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors.
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
- Therapeutic Activity of High-Dose IntratumOral IFN-β Requires Direct Effect on the Tumor Vasculature.
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic Melanoma: SWOG 0933.
- Effect of selumetinib vs chemotherapy on progression-free survival in uveal Melanoma: a randomized clinical trial.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Innate and adaptive Immune cells in the tumor microenvironment.
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells.
- Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Anergy InDuction.
- Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.
- Type I interferon response and innate immune sensing of Cancer.
- Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients.
- Ocular Melanoma metastasis to the cervical spine.
- The Immune Score as a New Possible Approach for the Classification of Cancer.
- Defining the Critical Hurdles in Cancer Immunotherapy.
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
- Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
- Molecular profiling of Melanoma and the evolution of patient-specific therapy.
- Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation.
- Evidence implicating the ras pathway in multiple CD28 costimulatory functions in CD4 T cells.
- Gene signature in melanoma associated with clinical activity: a potential clue to unlock Cancer immunotherapy.
- Beta-catenin does not regulate memory T cell phenotype.
- A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
- PD-1/PD-L1 interactions inhibit antitumor Immune responses in a murine acute myeloid leukemia model.
- Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.
- Chemokine expression in Melanoma metastases associated with CD8+ T-cell recruitment.
- Phase I/II trial of tremelimumab in patients with metastatic Melanoma.
- The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate Cancer.
- Emerging strategies in regulatory T-cell immunotherapies.
- Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 Melanoma.
- Diagnosis and treatment of mycoplasma-contaminated cell cultures.
- Farnesyltransferase inhibitors inhibit T-cell cytokine proDuction at the posttranscriptional level.
- Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment.
- Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
- Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
- The expanding universe of regulatory T cell subsets in Cancer.
- An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
- On the TRAIL toward death receptor-based Cancer therapeutics.
- T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha.
- Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.
- InDuction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
- Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
- Immune suppression in the tumor microenvironment.
- ProDuction of TH1 and TH2 cell lines and clones.
- Innovations and challenges in Melanoma: summary statement from the first Cambridge conference.
- Identifying and overcoming Immune resistance mechanisms in the melanoma tumor microenvironment.
- Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells.
- Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced Melanoma.
- Glucose availability regulates IFN-gamma proDuction and p70S6 kinase activation in CD8+ effector T cells.
- ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.
- Lymphoma-infiltrating Immune cells.
- Metabolic mechanisms of tumor resistance to T cell effector function.
- Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic Malignancies.
- Semiquantitative analysis of dynamic contrast enhanced MRI in Cancer patients: Variability and changes in tumor tissue over time.
- Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells.
- Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced Melanoma.
- Update on vaccines for solid Tumors.
- Temozolomide for Melanoma: new toxicities and new opportunities.
- Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration.
- PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
- Negative regulation of T-cell function by PD-1.
- Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes.
- Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.
- Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines.
- B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
- Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in adv...
- Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation.
- Increasing tumor antigen expression overcomes "ignorance" to solid Tumors via crosspresentation by bone marrow-derived stromal cells.
- Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
- Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic Renal carcinoma: clinical and biologic activity.
- Allogeneic stem-cell transplantation of renal cell Cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
- Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
- T cell-NF-κB activation is required for tumor control in vivo.
- Primary Murine CD4+ T Cells Fail to Acquire the Ability to Produce Effector Cytokines When Active Ras Is Present during Th1/Th2 Differentiation.
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 proDuction and proliferation of CD8(+) T cells directly within...
- Interleukin 2 and concanavalin A stimulate interferon-gamma proDuction in a murine cytolytic T cell clone by different pathways.
- Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
- CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.
- A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
- Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1.
- Transplantation and the CD28/CTLA4/B7 pathway.
- Allogeneic peripheral blood stem cell transplantation for metastatic Renal cell carcinoma.
- Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine pho...
- Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene deLivery in naive T cells.
- Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR Tumors by Stat6-deficient mice.
- Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
- Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.
- Monitoring specific T-cell responses to Melanoma vaccines: ELISPOT, tetramers, and beyond.
- Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
- Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide.
- The Immune system as anti-tumor sentinel: molecular requirements for an anti-tumor Immune response.
Schools
University of Chicago
University Of Chicago Hosps
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
University of Chicago -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1194888610 | |
| NPPES Provider LastName | GAJEWSKI | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 115.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194888610 |
| Last Name Of The Provider | GAJEWSKI |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Harvey M. Golomb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Stock, MD |
|
|
Dr. Joseph M. Baron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Hannigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hedy L. Kindler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd L. Zimmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucy A. Godley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rita Nanda, MD |
|
|
Dr. Christopher K. Daugherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Brittany Beach
This Doctor is OpenDoctor Recommended.
|